The need for non-invasive diagnosis and monitoring of NASH
Nonalcoholic steatohepatitis (NASH) is a chronic liver disease and is increasing in prevalence as an etiology for end-stage liver disease and also hepatocellular carcinoma. NASH is often a silent...
View ArticleIs Not Dying Yet on your bucket list?
The Fatty Liver Foundation exists because I was not willing to be a well behaved member of the parade of misery that liver disease is becoming for our society. My bucket list includes not dying of...
View ArticleLipids versus hepatic inflammation: a lysosomal interplay
The consumption of a healthy diet in combination with regular physical exercise is essential for an optimal and healthy condition, keeping the body in good shape. Although dietary guidelines may help...
View ArticleThe Burden Of NASH
The burden of non-alcoholic fatty liver disease (NAFLD) continues to increase at an alarming rate. The prevalence of disease equals the prevalence of metabolic syndrome (nearly 30% of the adult...
View ArticleA novel NOX1 and NOX4 inhibitor, an EMA reflection paper on drug development,...
Following the 2nd Global NASH Congress, we have made the following presentation slides from Alexandre Grassin, Elmer Schabel & Luca Valenti available. GKT831: A novel PII anti-fibrotic small...
View ArticleThe Genetics of progressive NAFLD
Over the last decade, the understanding of genetic factors impacting progressive liver disease has greatly increased. At the 2nd Global NASH Congress, Associate Professor at the University of Milan,...
View ArticleStem cell based anti-NASH drug testing: a pragmatic approach for a complex...
Non-alcoholic fatty liver disease (NAFLD) ranges from simple hepatic steatosis to severe, life-threatening non-alcoholic steatohepatitis (NASH). Steatosis is mostly asymptomatic and does not cause...
View ArticleInhibiting NOX enzymes to treat multiple diseases with high medical need
NOX enzymes are a family of enzymes which amplify multiple signaling pathways associated with liver disease. At the Global NASH Congress, Alexandre Grassin shared a presentation about Genkyotex’s novel...
View ArticleThe EMA reflection paper on chronic liver disease and its implications for...
The European Medicines Agency published a “Reflection paper on chronic liver diseases (PBC, PSC, and NASH)” in Autumn 2018. Elmer Schabel gives a detailed display of the contents of this first...
View ArticleUnderstanding the Role of the Gut Microbiome in NAFLD
NAFLD is the primary contributor to chronic liver disease worldwide with incident rates of 20-30% in western countries and 5-18% in Asia. The discovery of early stage biomarkers for patients with the...
View ArticleDeveloping successful treatments for HCC and NASH
Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the second most common cause of cancer deaths worldwide.[1] There is not currently a successful therapy to treat HCC in advanced...
View ArticleScreening for NAFLD in primary care: a preventative wonder or are we barking...
The burden of chronic liver disease has a substantial health and economic burden within the UK. Chronic liver disease is the fifth most common cause of death in the UK and of those five, it is the only...
View ArticleNovel biomarkers and the development of a point-of-care test for fatty liver...
Ahead of The 3rd Global NASH Congress, Dr Bevin Gangadharan explains how he helped to discover novel NAFLD biomarkers and their role in the development of a point-of-care test for NAFLD. Professors...
View ArticleUnderstanding the gut-liver axis: implications for NAFLD prevention and...
You may have heard; humans are superorganisms. The human large intestine harbors tens of trillions of microbes, which equates to roughly 2 kg of cells. For reference, that’s how much your brain...
View ArticleAn Overview of Available Preclinical Models for Non-alcoholic Fatty Liver...
NASH is thought to affect 25% of the global population and is a primary risk factor for Hepatocellular carcinoma (HCC) – the second most common cause of cancer deaths worldwide. Understanding the...
View ArticleDrug Development for NASH with Fibrosis: Expedited Programs
George Makar spoke at the Global NASH Congress. He gave a regulatory perspective on Drug Development for NASH with Fibrosis. The views were his own. In part one, we explore expedited programs. Watch...
View ArticleAdvancement in Therapeutics: Anti-Obesity Medications
Scott Harris, the Chief Medical Officer of Altimmune, gave a keynote address at the 6th Global NASH Congress where he discussed the development of drugs for both obesity and the treatment of NASH. He...
View ArticleUnravelling the Complexity of NAFLD: Insights from Professor Chris Byrne’s...
The 6th Global NASH Congress in London witnessed an enlightening presentation by Professor Chris Byrne, a distinguished metabolic physician and endocrinologist. His comprehensive exploration of...
View Article
More Pages to Explore .....